The $1 Trillion Club Gets a Little More Crowded

Micron’s rapid ascent to a $1 trillion valuation highlights the intense demand for high-bandwidth memory (HBM) driven by AI infrastructure, though the cyclical nature of the semiconductor industry remains a significant long-term risk. Eli Lilly continues to expand its medical portfolio through strategic acquisitions and promising Phase 1b trial results for a gene-editing therapy targeting cholesterol, shifting the focus from chronic daily management to one-time preventative care. Meanwhile, Zscaler’s stock experienced a sharp decline following earnings guidance that missed expectations, largely due to increased AI-related capital expenditures and recent executive turnover. Despite this volatility, the core cybersecurity business remains robust, suggesting that current market reactions may be overblown relative to the company's long-term growth potential in an increasingly complex digital threat landscape.